![Ocugen, Inc. logo](/logos/OCGN.webp)
Ocugen, Inc.
NASDAQ:OCGN
Overview | Financials
Company Name | Ocugen, Inc. |
Symbol | OCGN |
Currency | USD |
Price | 1.14 |
Market Cap | 328,158,120 |
Dividend Yield | 0% |
52-week-range | 0.345 - 2.105 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Shankar Musunuri M.B.A., MBA, Ph.D. |
Website | https://www.ocugen.com |
An error occurred while fetching data.
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD